1783 — Maxigen Biotech Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesSpeculativeSmall CapFalling Star

Annual income statement for Maxigen Biotech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	452	458	512	604	622
Cost of Revenue
Gross Profit	217	215	261	374	424
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses	387	397	422	476	472
Operating Profit	65.6	61.1	89.9	129	150
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	72.8	76.7	97.5	166	193
Provision for Income Taxes
Net Income After Taxes	60.1	63.3	87.7	139	166
Net Income Before Extraordinary Items
Net Income	60.1	63.3	87.7	139	166
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	62.6	63.3	87.7	139	166
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.713	0.785	1.04	1.55	1.86
Dividends per Share